Lipigon Pharmaceuticals (LPGO) Q3 2025 earnings summary

Executive summary

• Completed last patient visit in the three-month follow-up of the phase II clinical study for Lipisense®, with preliminary top-line data expected before year-end.

• Management team restructured in August to enhance strategic development ahead of study results.

• Engaged in business development and partnership discussions within the cardiometabolic field.

• Participated in a major life science business conference, increasing visibility and networking.

Financial highlights

• Net sales were SEK 0 for both Q3 and the nine-month period, compared to SEK 8,970k in the same period last year.

• Operating loss for Q3 was SEK -7,442k (Q3 2024: -6,722k); for Jan–Sep, SEK -24,993k (Jan–Sep 2024: -14,493k).

• Net loss per share for Jan–Sep was SEK -0.09 (Jan–Sep 2024: -0.11).

• Cash and cash equivalents at period end were SEK 16,597k (Sep 2024: 10,736k).

Outlook and guidance

• Preliminary top-line data from the phase II Lipisense® study expected before year-end.

• Continued focus on business development and potential partnerships, especially if clinical results are positive.

• Ongoing efforts to secure financing for continued operations, contingent on positive clinical outcomes.